A benefit observed after the final study administration is a follow-up finding, not proof of a permanent change. Online questions about how long Selank “sticks around” often combine several different ideas: how long the substance remains present, how long a symptom changes and whether an underlying disorder has been durably altered.
The 2014 human comparative study abstract describes an anxiety-related effect persisting for a week after treatment ended. That is a specific, short observation within that study. It does not establish benefit months later, prevention of relapse or a reliable response in a new patient.
Duration claims need a clearly defined endpoint. A questionnaire score remaining improved is not identical to a participant no longer meeting diagnostic criteria. Neither result alone would show that a biological pathway had been permanently reset. The wording should follow what was actually measured rather than the most expansive interpretation of the experience.
Follow-up also needs a suitable comparison. Symptoms can fluctuate, and other care or changes in circumstances may continue after a study intervention ends. Without enough detail about those factors, a summary should preserve uncertainty about the cause and persistence of the difference. Individual testimonials provide even less control over those explanations.
The evidence reviewed here does not establish a cycle length, a break between courses or a maintenance plan. Turning a short follow-up interval into such advice would add a treatment strategy the abstract did not test. It would also assume that recreating a reported symptom pattern is both beneficial and safe.
For a clinician, the relevant question is whether a person has sustained improvement in the outcomes that matter to them, with acceptable risks and a clear plan for ongoing care. That assessment cannot be replaced by counting days since an investigational product was used. Prescribed medicines should not be changed on the basis of this article.
The full Russian-language methods and longer-term individual outcomes were not assessed here. The defensible conclusion is therefore limited: a short persistence signal was reported, while permanent benefit and validated repeated-use strategies remain unestablished by this source. Clear boundaries are more informative than either a promise of lasting repair or a categorical claim that no effect could persist.